PDCD1 and neoplasm: In the United States, these PD-1 inhibitors are also approved for patients with high TMB, as these tumours tend to harbour numerous somatic mutations, leading to increased neoantigen presentation and enhanced susceptibility of immune checkpoint inhibition [115].